Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01801293 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study to Evaluate the Pharmacokinetics, Metabolism, and Excretion of GS-5806
A Phase 1 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT01801293 is a Phase 1 study that has completed, run by Gilead Sciences. The registered enrollment target is 8 participants.
The verdict
NCT01801293, a Phase 1 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
This is a single center, open-label, Phase 1 study to determine the mass balance of of GS-5806 following administration of a single, oral dose of radiolabeled \[14C\]-GS-5806 in healthy subjects.
Interventions
- DRUG GS-5806
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2013-03 |
| Est. Completion | 2013-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01801293
The ClinicalTrials.gov registry entry for NCT01801293 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GS-5806 is the first listed.
NCT01801293 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01801293 about?
NCT01801293 is a clinical study titled "A Phase 1 Study to Evaluate the Pharmacokinetics, Metabolism, and Excretion of GS-5806". This is a single center, open-label, Phase 1 study to determine the mass balance of of GS-5806 following administration of a single, oral dose of radiolabeled \[14C\]-GS-5806 in healthy subjects.
What is the current status of trial NCT01801293?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2013-03. Estimated completion is 2013-04.
What interventions are being tested in trial NCT01801293?
The interventions under investigation include: GS-5806 (DRUG).
Who is sponsoring clinical trial NCT01801293?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.